Short-term testosterone linked to VTE

Testosterone therapy is associated with an increased short-term risk for venous thromboembolism (VTE), according to a study published in JAMA Internal Medicine. The association was the same in men with or without hypogonadism.

A total of 39 622 men (mean age, 57.4 years) were enrolled in the case-controlled study (7.8% had evidence of hypogonadism). Testosterone therapy use six, three and one month before the VTE event was associated with a higher risk of VTE in men with hypogonadism (odds ratio [OR], 2.32; 95% CI, 1.97–2.74) and without hypogonadism (OR, 2.02; 95% CI, 1.47–2.77.

According to the authors: ‘These data combined with prior data suggest that future clinical trials of testosterone therapy, regardless of the indication, should capture VTE events as part of safety end points.’

Web design and marketing agency Leamington Spa